503A

Ketamine ODT

503A

Ketamine ODT

100 mg150 mg200 mg250 mg

Ketamine ODT

$100.00

Add to cart
Buy Now

Product Overview

This product is available solely through our 503A Compounding Pharmacy, ensuring personalized care and precision in every order. Please note that a valid prescription is required for purchase. If you do not have an account, please contact us.

Ketamine ODT (Each)

100 mg150 mg200 mg250 mg

Form: Oral dissolvable tablet (off-label use)
Use: Depression, anxiety, PTSD, chronic pain

Mechanism of Action
NMDA receptor antagonist → increases glutamate → improves mood & neuroplasticity

Contraindications & Precautions
Contraindications: Allergy, uncontrolled hypertension, aneurysm
Precautions: Heart disease, psychosis, substance abuse

Interactions
CNS depressants: ↑ sedation
MAOIs: ↑ blood pressure risk
Caution with alcohol & stimulants

Adverse Reactions / Side Effects
Common: Dissociation, nausea, dizziness, drowsiness
Serious: High BP, hallucinations, dependence

Pregnancy: Avoid; may harm fetus
Breastfeeding: Not recommended

Store this medication at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

  1. Persson J. Wherefore ketamine? Curr Opin Anaesthesiol. 2010;23:455–60.
  2. Stoelting RK, Hillier SC. Nonbarbiturate intravenous anaesthetic drugs. In: Stoelting RK, Hillier SC, editors. Pharmacology and Physiology in Anaesthetic Practice. 4th ed. Philadelphia: Lippincott Williams and Wilkin; 2006. pp. 155–78
  3. Reynolds JEF, Parfitt K, Parsons AV, Sweetman SC (eds.). Martindale, the extra pharmacopoeia. 29th Edition.The Pharmaceutical Press: London, 1989.
  4. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989;36:186-97.
  5. Hansen G, Jensen SB, Chandresh L, Hilden T. The psychotropic effect of ketamine. J Psychoactive Drugs 1988;20:419-425.
  6. Malinovsky JM, Servin F, Cozia A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth 1996;77:203-207.
  7. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 1981;53:805-10.
  8. Errando CL, Sifre C, Moliner S, Valia JC, Gimeno O, Minguez A, Boils P. Subarachnoid ketamine in swine-pathological findings after repeated doses: acute toxicity study. Reg Anesth Pain Med 1999;24:146-52.
  9. Malinovsky JM, Lepage JY, Cozian A, Mussini JM, M Pinaudt M, Souron R. Is ketamine or its preservative responsible for neurotoxicity in the rabbit? Anesthesiology 1993;78:109-15.
  10. Hirota K, Lambert DG. Ketamine: New uses for an old drug? Br J Anaesth. 2011;107:123–6
  11. Yoon SH. Concerns of the anesthesiologist: Anesthetic induction in severe sepsis or septic shock patients. Korean J Anesthesiol. 2012;63:3–10.
  12. Sleigh J, Harvey M, Voss L, Denny B. Ketamine-more mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care. 2014;4:76-81
  13. White JM, Ryan CF. Pharmacological properties of ketamine. Drug Alc Review 1996;15:145-155.
  14. Bergman SA. Ketamine: review of its pharmacology and its use in pediatric anesthesia. Anesth Prog 1999;46:10-20.
  15. Green SM, Clark R, Hostetler MA, Cohen M, Carlson D, Rothrock SG. Inadvertent ketamine overdose in children: clinical manifestations and outcome. Annals of emergency medicine. 1999; 34(4): 492-497.
  16. Kopman AF. To the editor: ketamine may interact with barbiturate premedication in producing delayed awakening from anesthesia and significant respiratory depression. Anesth. Analg. 1972;51:793-4.
  17. Moore KA, Kilbane EM, Jones R, Kunsman GW, Levine B, Smith M. Tissue distribution of ketamine in a mixed drug fatality. J Forensic Sci 1997;42:1183-5.
  18. Murphy JL Jr. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anaesth 1993;40:160-4.
  19. Noppers IM, Niesters M, Aarts LP, Bauer MC, Drewes AM, Dahan A, Sarton EY. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain. 2011 Sep;152(9):2173-8.

Related medications

503A vs 503B

  • 503A pharmacies compound products for specific patients whose prescriptions are sent by their healthcare provider.
  • 503B outsourcing facilities compound products on a larger scale (bulk amounts) for healthcare providers to have on hand and administer to patients in their offices.

Frequently asked questions

Our team of experts has the answers you're looking for.

A clinical pharmacist cannot recommend a specific doctor. Because we are licensed in Arizona, California, New Mexico, Texas, we can accept prescriptions from many licensed prescribers if the prescription is written within their scope of practice and with a valid patient-practitioner relationship.

*Licensing is subject to change.

Each injectable IV product will have the osmolarity listed on the label located on the vial.

Given the vastness and uniqueness of individualized compounded formulations, it is impossible to list every potential compound we offer. To inquire if we currently carry or can compound your prescription, please fill out the form located on our Contact page or call us at (806) 744-8477.

We source all our medications and active pharmaceutical ingredients from FDA-registered suppliers and manufacturers.

We're licensed to ship Arizona, California, New Mexico and Texas.

We ship orders directly to you, quickly and discreetly.

Ready to get started?